KoBioLabs, Inc (KOSDAQ:348150)
South Korea · Delayed Price · Currency is KRW 3,780.00
+170.00 (4.71%)
At close: Jun 5, 2026
KoBioLabs Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 71,212 | 69,292 | 68,359 | 33,138 | 11,606 | 2,893 |
Other Revenue | -0 | -0 | - | - | -0 | -0 |
| 71,212 | 69,292 | 68,359 | 33,138 | 11,606 | 2,893 | |
Revenue Growth (YoY) | 0.61% | 1.36% | 106.29% | 185.53% | 301.12% | -36.98% |
Cost of Revenue | 18,719 | 18,267 | 21,565 | 9,429 | 3,627 | 995.01 |
Gross Profit | 52,493 | 51,025 | 46,794 | 23,709 | 7,979 | 1,898 |
Selling, General & Admin | 53,619 | 52,591 | 46,134 | 27,321 | 13,675 | 5,580 |
Research & Development | 7,200 | 7,572 | 6,905 | 14,262 | 14,198 | 12,496 |
Amortization of Goodwill & Intangibles | 79.69 | 76.85 | 68.43 | 67.5 | 72.32 | 65.6 |
Other Operating Expenses | 110.29 | 96.36 | 196 | 173.28 | 163.74 | 25.93 |
Operating Expenses | 61,349 | 60,676 | 53,699 | 42,167 | 28,270 | 18,236 |
Operating Income | -8,856 | -9,651 | -6,905 | -18,458 | -20,292 | -16,337 |
Interest Expense | -480.84 | -512.4 | -1,158 | -1,532 | -1,683 | -152.59 |
Interest & Investment Income | 1,573 | 1,572 | 2,408 | 3,253 | 2,135 | 499.93 |
Currency Exchange Gain (Loss) | 3,376 | 1,342 | 1,010 | 653.71 | 36.2 | 113.34 |
Other Non Operating Income (Expenses) | 105.66 | 114.09 | 144.16 | 1,384 | -3,223 | -498.84 |
EBT Excluding Unusual Items | -4,283 | -7,136 | -4,501 | -14,700 | -23,026 | -16,376 |
Gain (Loss) on Sale of Investments | 199.81 | 191.75 | - | - | 11.51 | 7.08 |
Gain (Loss) on Sale of Assets | - | - | -123.43 | - | -15.41 | 0.26 |
Other Unusual Items | - | - | 447.05 | 16.99 | - | - |
Pretax Income | -4,083 | -6,945 | -4,178 | -14,683 | -23,030 | -16,368 |
Income Tax Expense | 27.13 | 27.13 | 439.17 | 475.14 | 355.52 | -986.27 |
Earnings From Continuing Operations | -4,110 | -6,972 | -4,617 | -15,158 | -23,386 | -15,382 |
Minority Interest in Earnings | 381.97 | 641.99 | -681.1 | 1,305 | 1,464 | - |
Net Income | -3,728 | -6,330 | -5,298 | -13,853 | -21,921 | -15,382 |
Net Income to Common | -3,728 | -6,330 | -5,298 | -13,853 | -21,921 | -15,382 |
Shares Outstanding (Basic) | - | 19 | 19 | 19 | 17 | 16 |
Shares Outstanding (Diluted) | - | 19 | 19 | 19 | 17 | 16 |
Shares Change (YoY) | - | 1.11% | 3.61% | 10.30% | 4.68% | 49.69% |
EPS (Basic) | - | -326.14 | -276.00 | -747.72 | -1305.15 | -958.62 |
EPS (Diluted) | - | -326.14 | -276.00 | -748.00 | -1305.15 | -959.00 |
Free Cash Flow | -2,969 | -6,081 | -5,995 | -28,966 | -31,239 | -17,993 |
Free Cash Flow Per Share | - | -313.32 | -312.34 | -1563.45 | -1859.88 | -1121.36 |
Gross Margin | 73.71% | 73.64% | 68.45% | 71.55% | 68.75% | 65.61% |
Operating Margin | -12.44% | -13.93% | -10.10% | -55.70% | -174.84% | -564.66% |
Profit Margin | -5.24% | -9.13% | -7.75% | -41.80% | -188.89% | -531.63% |
Free Cash Flow Margin | -4.17% | -8.78% | -8.77% | -87.41% | -269.17% | -621.88% |
EBITDA | -6,069 | -6,874 | -4,327 | -16,943 | -19,383 | -16,105 |
EBITDA Margin | -8.52% | -9.92% | -6.33% | -51.13% | -167.02% | - |
D&A For EBITDA | 2,787 | 2,777 | 2,578 | 1,515 | 908.06 | 232.72 |
EBIT | -8,856 | -9,651 | -6,905 | -18,458 | -20,292 | -16,337 |
EBIT Margin | -12.44% | -13.93% | -10.10% | -55.70% | -174.84% | - |
Advertising Expenses | - | 17,410 | 14,172 | 7,806 | 3,478 | 717.8 |